2009 in oncology

The approvals rows on treatment records: region, year and indication.

• 2009Bevacizumab (glioblastoma use) approved in US

  Recurrent glioblastoma (accelerated; full approval 2017)

• 2009Catumaxomab approved in EU

  Malignant ascites in EpCAM-positive carcinomas when standard therapy is unavailable (Removab; withdrawn 2017)

• 2009Degarelix approved in EU

  Same

• 2009Epoetin theta approved in EU

  Symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy; anaemia of chronic renal failure.

• 2009Everolimus approved in US

  Advanced RCC after sunitinib or sorafenib

• 2009Gefitinib approved in EU

  EGFR-mutant NSCLC

• 2009HPV bivalent vaccine (types 16 and 18) approved in US

  Prevention of cervical cancer and precursor lesions caused by HPV 16 and 18 in females 10 to 25 (discontinued in the US 2016)

• 2009Ibritumomab tiuxetan approved in US

  Consolidation after first-line chemotherapy in previously untreated follicular NHL

• 2009Mifamurtide approved in EU

  High-grade resectable non-metastatic osteosarcoma after complete resection, with chemotherapy, ages 2-30

• 2009Ofatumumab approved in US

  CLL refractory to fludarabine and alemtuzumab (accelerated)

• 2009Pazopanib approved in US

  Advanced renal cell carcinoma

• 2009Plerixafor approved in EU

  Stem cell mobilisation with G-CSF in lymphoma and multiple myeloma with poor mobilisation (Mozobil)

• 2009Pralatrexate approved in US

  Relapsed/refractory peripheral T-cell lymphoma

• 2009Romidepsin approved in US

  Cutaneous T-cell lymphoma after ≥1 systemic therapy

• 2009Topotecan approved in England (NICE)

  Relapsed small-cell lung cancer, oral topotecan, only where re-treatment with the first-line regimen is inappropriate and cyclophosphamide, doxorubicin and vincristine is contraind...

• 2009Trabectedin approved in EU

  Relapsed platinum-sensitive ovarian cancer with PLD

• 2009Vinflunine approved in EU

  Advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen

The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.

• 2009Family Smoking Prevention and Tobacco Control Act 2009

  United States, statute.

• 2009Supplementary protection certificate (EU)

  European Union, regulation.

The year reported on trial records, with the headline result the record gives.

• 2009A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma reported
  Multiple myelomaPlitidepsin
• 2009AZA-001 reported

  Azacitidine improved overall survival over conventional care regimens in higher-risk myelodysplastic syndromes.

  Higher-risk myelodysplastic syndromesMyelodysplastic syndromes / neoplasms (MDS)Azacitidine
• 2009CRYSTAL & FIRE-3 reported

  CRYSTAL KRAS-WT OS 23.5 vs 20.0 months; FIRE-3 OS 28.7 vs 25.0 months.

  Colorectal cancerCetuximabBevacizumabFOLFIRI (5-FU, leucovorin, irinotecan)
• 2009EORTC 22961 reported

  Five-year overall mortality 19.0 percent with 6 months of androgen suppression against 15.2 percent with 3 years; hazard ratio 1.42, non-inferiority not shown (p=0.65).

  Prostate cancerLocalised prostate cancer, high and very high risk
• 2009MRC CR07 reported

  Local recurrence at three years 4.4 percent with short-course preoperative radiotherapy against 10.6 percent with selective postoperative chemoradiotherapy (hazard ratio 0.39, 0.27...

  Colorectal cancerRectal cancer
• 2009Osmanabad cervical screening trial (HPV testing vs cytology vs VIA) reported

  Cervical cancer deaths HR 0.52 with one round of HPV testing; no significant effect of cytology or VIA.

  Cervical cancer
• 2009PATRICIA reported

  Vaccine efficacy against CIN2+ associated with HPV-16/18 92.9% (96.1% CI 79.9 to 98.3) in the according-to-protocol efficacy cohort; 98.1% with HPV-type causality assigned.

  Cervical cancerHPV bivalent vaccine (types 16 and 18)
• 2009PETACC-3 reported

  Five-year disease-free survival 56.7 against 54.3 percent (p=0.106); no overall survival gain.

  Colorectal cancerColon cancer (adenocarcinoma of the colon)Irinotecan (and liposomal irinotecan)Fluorouracil (5-FU)
• 2009PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) reported

  Prostate cancer death rate 2.0 against 1.7 per 10,000 person-years, rate ratio 1.13 (95 percent confidence interval 0.75 to 1.70), not significant; control-group PSA testing rose f...

  Prostate cancer
• 2009PROMID reported

  TTP 14.3 vs 6.0 months, HR 0.34.

  Neuroendocrine tumoursSmall intestinal neuroendocrine tumoursSomatostatin analogues (octreotide, lanreotide)
• 2009SIOPEL-3 reported

  Complete resection 95 percent with cisplatin alone against 93 percent with cisplatin plus doxorubicin; three-year overall survival 95 against 93 percent; grade 3 or 4 toxicity 20.6...

  HepatoblastomaChildhood cancers (all types)CisplatinDoxorubicin
• 2009SPCG-7/SFUO-3 reported

  Ten-year prostate cancer mortality 11.9 percent with hormones plus radiotherapy against 23.9 percent with hormones alone (relative risk 0.44, 95 percent confidence interval 0.30 to...

  Prostate cancerLocalised prostate cancer, high and very high riskFlutamide
• 2009SWOG 8794 reported

  Metastasis-free survival hazard ratio 0.71 (95 percent confidence interval 0.54 to 0.94, p=0.016) and overall survival hazard ratio 0.72 (0.55 to 0.96, p=0.023) with adjuvant radio...

  Prostate cancerLocalised prostate cancer, high and very high riskBiochemical recurrence of prostate cancer

The publication year on key paper records.

• 2009A subtype of childhood acute lymphoblastic leukaemia with poor outcome: genome-wide classification study (BCR-ABL1-like ALL)

  Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. The Lancet Oncology.

• 2009AALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children

  Schultz KR, Bowman WP, Aledo A, et al. Journal of Clinical Oncology.

• 2009Adaptive therapy

  Gatenby RA, Silva AS, Gillies RJ, et al. Cancer Research.

• 2009AZA-001: azacitidine versus conventional care in higher-risk myelodysplastic syndromes

  Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. The Lancet Oncology.

• 2009Cancer stem cells: mirage or reality?

  Gupta PB, Chaffer CL, Weinberg RA. Nature Medicine.

• 2009Cell cycle, CDKs and cancer: a changing paradigm

  Malumbres M, Barbacid M. Nature Reviews Cancer.

• 2009Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)

  Van Cutsem E, Köhne CH, Hitre E, et al. New England Journal of Medicine.

• 2009Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: multi-institutional registry

  Yan TD, Deraco M, Baratti D, et al. Journal of Clinical Oncology.

• 2009Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

  Koopman M, Kortman GA, Mekenkamp L, et al. British Journal of Cancer.

• 2009Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia

  Mullighan CG, Su X, Zhang J, et al. New England Journal of Medicine.

• 2009DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer

  Iacobuzio-Donahue CA, Fu B, Yachida S, et al. Journal of Clinical Oncology.

• 2009Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial

  Sjöström L, Gummesson A, Sjöström CD, et al. The Lancet Oncology.

• 2009Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis

  Paavonen J, Naud P, Salmerón J, et al. The Lancet.

• 2009ERSPC: screening and prostate cancer mortality in a randomised European study

  Schröder FH, Hugosson J, Roobol MJ, et al. New England Journal of Medicine.

• 2009Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis

  Fluge Ø, Gravdal K, Carlsen E, et al. British Journal of Cancer.

• 2009Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  Mok TS, Wu YL, Thongprasert S, et al. New England Journal of Medicine.

• 2009Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

  Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. New England Journal of Medicine.

• 2009Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1

  Ligtenberg MJ, Kuiper RP, Chan TL, et al. Nature Genetics.

• 2009Homeopathic medicines for adverse effects of cancer treatments

  Kassab S, Cummings M, Berkovitz S, et al. The Cochrane database of systematic reviews.

• 2009HPV screening for cervical cancer in rural India (Osmanabad)

  Sankaranarayanan R, Nene BM, Shastri SS, et al. New England Journal of Medicine.

• 2009Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

  Olive KP, Jacobetz MA, Davidson CJ, et al. Science.

• 2009Jemal 2009: Cancer statistics, 2009

  Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. CA: A Cancer Journal for Clinicians.

• 2009Kalluri and Weinberg 2009: the basics of epithelial-mesenchymal transition

  Kalluri R, Weinberg RA. Journal of Clinical Investigation.

• 2009Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

  Draisma G, Etzioni R, Tsodikov A, et al. JNCI: Journal of the National Cancer Institute.

• 2009Management of lung nodules detected by volume CT scanning

  van Klaveren RJ, Oudkerk M, Prokop M, et al. New England Journal of Medicine.

• 2009Matrix crosslinking forces tumor progression by enhancing integrin signaling

  Levental KR, Yu H, Kass L, et al. Cell.

• 2009Mutation of FOXL2 in granulosa cell tumours of the ovary

  Shah SP, Köbel M, Senz J, et al. New England Journal of Medicine.

• 2009No surgical innovation without evaluation: the IDEAL recommendations

  McCulloch P, Altman DG, Campbell WB, et al. The Lancet.

• 2009Oncogenic EGFR signaling networks in glioma

  Huang PH, Xu AM, White FM. Science signaling.

• 2009Phase 2 study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater

  Overman MJ, Varadhachary GR, Kopetz S, et al. Journal of Clinical Oncology.

• 2009PLCO: mortality results from a randomised prostate cancer screening trial

  Andriole GL, Crawford ED, Grubb RL, et al. New England Journal of Medicine.

• 2009Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016)

  Sebag-Montefiore D, Stephens RJ, Steele R, et al. The Lancet.

• 2009Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control

  Bonvalot S, Rivoire M, Castaing M, et al. Journal of Clinical Oncology.

• 2009Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: result...

  Heng DY, Xie W, Regan MM, et al. Journal of Clinical Oncology.

• 2009Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study

  Schmid P, Nagai Y, Agarwal R, et al. The Lancet.

• 2009PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours

  Rinke A, Müller HH, Schade-Brittinger C, et al. Journal of Clinical Oncology.

• 2009Prospective multi-institutional study of adjuvant radiotherapy after resection of borderline and malignant phyllodes tumours

  Barth RJ, Wells WA, Mitchell SE, et al. Annals of surgical oncology.

• 2009Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005

  Welch HG, Albertsen PC. JNCI: Journal of the National Cancer Institute.

• 2009Recurrent fusion of MYB and NFIB transcription factor genes in adenoid cystic carcinoma

  Persson M, Andrén Y, Mark J, et al. Proceedings of the National Academy of Sciences.

• 2009Sato 2009: single Lgr5 stem cells build crypt-villus organoids

  Sato T, Vries RG, Snippert HJ, et al. Nature.

• 2009SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

  Perilongo G, Maibach R, Shafford E, et al. New England Journal of Medicine.

• 2009Supervised risk predictor of breast cancer based on intrinsic subtypes

  Parker JS, Mullins M, Cheang MC, et al. Journal of Clinical Oncology.

• 2009The cancer genome

  Stratton MR, Campbell PJ, Futreal PA. Nature.

• 2009The International Neuroblastoma Risk Group (INRG) classification system

  Cohn SL, Pearson AD, London WB, et al. Journal of Clinical Oncology.

• 2009The microenvironment in mature B-cell malignancies: a target for new treatment strategies

  Burger JA, Ghia P, Rosenwald A, et al. Blood.

• 2009Understanding the Warburg effect: the metabolic requirements of cell proliferation

  Vander Heiden MG, Cantley LC, Thompson CB. Science.

• 2009Weight lifting in women with breast-cancer-related lymphedema

  Schmitz KH, Ahmed RL, Troxel A, et al. New England Journal of Medicine.

The history entries editors wrote on cancer records: the dated turning points of each disease.

• 2009AALL0031: continuous imatinib with chemotherapy gives 80 percent three-year event-free survival

  Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)

  Imatinib
• 2009ACOSOG Z9001: one year of adjuvant imatinib reduces recurrence

  KIT exon 11-mutant GIST

  Imatinib
• 2009AZA-001: azacitidine lengthens survival in higher-risk MDS

  Higher-risk myelodysplastic syndromes

  Azacitidine
• 2009Bethesda System for thyroid cytology standardises nodule reporting

  Thyroid cancer

  Bethesda category (thyroid cytology)Thyroid nodule FNA, Bethesda cytology & molecular classifiers
• 2009Bevacizumab accelerated approval at recurrence

  Glioma & glioblastoma. Radiographic response without survival benefit.

  Bevacizumab (glioblastoma use)
• 2009Bevacizumab shrinks NF2 vestibular schwannomas and improves hearing

  Vestibular schwannoma (acoustic neuroma). Plotkin and colleagues (NEJM).

  Bevacizumab
• 2009CAPOX phase 2 establishes oxaliplatin-fluoropyrimidine as first-line therapy

  Advanced and metastatic small bowel adenocarcinoma

  CAPOX (capecitabine, oxaliplatin)
• 2009Charing Cross series identifies an interval of over four years as the strongest predictor of death

  Placental-site trophoblastic tumour and epithelioid trophoblastic tumour

• 2009Conformal radiotherapy safe and effective in young children

  Ependymoma. St Jude RT1 (Merchant, Lancet Oncology) shows tumour-bed irradiation controls disease with preserved cognition.

  IMRT / IGRT (modern external beam)
• 2009DICER1 germline mutations cause familial PPB

  Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours). Hill and colleagues (Science) identify the first microRNA-processing gene tumour syndrome.

• 2009ENSAT staging

  Adrenocortical carcinoma

• 2009ENSAT staging system published

  Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)

  Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)
• 2009EPCAM deletions as a cause of Lynch syndrome

  Colorectal cancer. Loss of the 3' exons of EPCAM silences the neighbouring MSH2 gene by transcriptional read-through, in EpCAM-expressing tissue only.

  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1EpCAM
• 2009Everolimus approved second line (RECORD-1)

  Renal cell carcinoma

  Everolimus
• 2009First report of a metastatic medulloblastoma responding to a smoothened inhibitor

  SHH-activated medulloblastoma

  Vismodegib
• 2009FOXL2 C134W mutation found in almost all adult granulosa cell tumours

  Adult granulosa cell tumour of the ovary

• 2009Germline TBXT duplication in familial chordoma

  Chordoma. Yang and colleagues (Nat Genet).

• 2009GNAQ mutations discovered (Van Raamsdonk); GNA11 in 2010

  Uveal melanoma

• 2009GOG-0204: cisplatin-paclitaxel confirmed as the reference doublet

  Recurrent or metastatic cervical cancer

  CisplatinPaclitaxel / nab-paclitaxel
• 2009Gronchi and Bonvalot report improved local control with extended en bloc resection

  Retroperitoneal sarcoma

• 2009HPV vaccination shown to prevent external genital lesions in men

  Localised penile cancer (organ-confined, node-negative)

  HPV & HBV vaccinationNonavalent HPV vaccine
• 2009IDH1 and IDH2 mutations define a glioma lineage

  Astrocytoma, IDH-mutant (grades 2 to 4). Yan and colleagues (NEJM) show IDH mutations in most grade 2 and 3 gliomas and their better prognosis.

  IDH1 / IDH2
• 2009IDH1 mutations found in AML after their discovery in glioma

  IDH1- and IDH2-mutated acute myeloid leukaemia

  IDH1 / IDH2
• 2009INRG classification defines the intermediate-risk group by stage, age and biology

  Intermediate-risk neuroblastoma

  INRG staging and risk groups
• 2009INRG classification unifies international risk grouping

  Neuroblastoma (paediatric)

  INRG staging and risk groups
• 2009International Neuroblastoma Risk Group classification published

  Low-risk neuroblastoma (INRG very low and low risk, including stage MS)

  INRG staging and risk groups
• 2009IPASS: gefitinib beats chemotherapy in EGFR-mutant patients, worse in others; testing becomes mandatory

  EGFR-mutated non-small-cell lung cancer

  GefitinibTony S. K. Mok
• 2009IPASS: the biomarker, not the population

  Lung cancer (all types). 1,217 East Asian never-smokers and light former smokers randomised between gefitinib and chemotherapy; the benefit lived entirely in the EGFR-mutant subgro...

  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
• 2009LAP2: laparoscopic hysterectomy equivalent to open surgery

  Endometrial cancer

  Robotic & minimally invasive surgery
• 2009Long-course beats short-course androgen deprivation with radiotherapy in high-risk disease

  Localised prostate cancer, high and very high risk

  Androgen deprivation & AR pathway inhibitors
• 2009MACH-NC update: concomitant chemotherapy adds about 6.5 points to five-year survival

  HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)

• 2009MRC CR07 settles the timing of rectal radiotherapy

  Colorectal cancer. 1,350 patients; local recurrence 61 percent lower with short-course radiotherapy before surgery than with selective postoperative chemoradiotherapy, with no surv...

  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016)
• 2009MRD becomes the key risk factor

  Acute lymphoblastic leukaemia. AIEOP-BFM 2000 and UKALL 2003 show end-of-induction MRD outperforms every clinical factor; MRD-directed therapy adopted.

  Multiparameter flow cytometry MRDMRD-negative complete remission
• 2009Multi-institutional registry of 405 patients

  Peritoneal mesothelioma. Yan and colleagues report median survival of 53 months after cytoreduction and HIPEC.

• 2009MYB-NFIB fusion identified as the defining genetic event

  Adenoid cystic carcinoma

• 2009MYB-NFIB fusion in adenoid cystic carcinoma (Persson, PNAS)

  Salivary gland cancers

• 2009NUT immunohistochemistry validated

  NUT carcinoma (midline carcinoma with NUTM1 rearrangement). Haack and colleagues: highly specific antibody enables diagnosis.

• 2009Ph-like (BCR-ABL1-like) ALL described by Dutch and US groups as a poor-prognosis subgroup

  Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)

• 2009Pralatrexate and romidepsin approved

  Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma). First drugs specifically for relapsed PTCL.

  PralatrexateRomidepsin
• 2009PROMID: octreotide LAR slows midgut tumour growth

  Small intestinal neuroendocrine tumours

  PROMIDSomatostatin analogues (octreotide, lanreotide)
• 2009PROMID: octreotide slows tumour growth

  Neuroendocrine tumours

  PROMID
• 2009Single-arm phase 2: no local recurrences after breast conservation with radiotherapy for borderline and malignant tumours

  Phyllodes tumour of the breast

  IMRT / IGRT (modern external beam)
• 2009SIOPEL-3: cisplatin alone suffices for standard risk (NEJM)

  Hepatoblastoma

  Cisplatin
• 2009Sunitinib shows activity in alveolar soft part sarcoma

  Alveolar soft part sarcoma

  Sunitinib
• 2009The 1 mm margin rule in UK pathology reporting

  Pancreatic ductal adenocarcinoma. Tumour within 1 mm of a margin is R1 (Royal College of Pathologists); standardised protocols raised the reported R1 rate to 76 to 85 percent of he...

  R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reportingResection margins (R0 / R1 / R2)
• 2009The two screening trials report on the same day and disagree

  Prostate cancer. ERSPC found a 20 percent reduction in prostate cancer mortality, at 1,410 men screened and 48 extra cancers treated per death prevented.

  ERSPC (European Randomized Study of Screening for Prostate Cancer)PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)ERSPC: screening and prostate cancer mortality in a randomised European studyPLCO: mortality results from a randomised prostate cancer screening trial
• 2009Transoral robotic surgery FDA-cleared

  Head and neck squamous cell carcinoma

  Transoral robotic surgery (TORS)
• 2009Vismodegib phase 1 shows responses in advanced BCC (NEJM)

  Basal cell carcinoma

  Vismodegib
• 2009Vismodegib phase 1: responses in advanced basal cell carcinoma (NEJM)

  Locally advanced and metastatic basal cell carcinoma

  Vismodegib

The since year on technology records: first use in humans or first approval, as the record states it.

• 2009Adaptive therapy (evolution-based dosing)

  First use in humans or first approval, as the technology record states it.

• 2009PI3K, AKT and mTOR inhibitors

  First use in humans or first approval, as the technology record states it.

• 2009Radiogenomics: predicting radiation sensitivity from genes

  First use in humans or first approval, as the technology record states it.

• 2009Transoral robotic surgery (TORS)

  First use in humans or first approval, as the technology record states it.

The founded year on company records.

• 2009Andreessen Horowitz Bio + Health founded

  Menlo Park, CA

• 2009Atossa Therapeutics founded

  Seattle, WA

• 2009ETOP IBCSG Partners Foundation founded

  Bern

• 2009GV (Google Ventures) founded

  Mountain View, CA

• 2009Suzhou Zelgen Biopharmaceuticals founded

  Suzhou

The founded year on journal records.

• 2009Cancer epidemiology founded

  Elsevier

• 2009Cancers founded

  MDPI

• 2009Oncotarget founded

  Impact Journals (Rapamycin Press LLC)

• 2009Science Translational Medicine founded

  American Association for the Advancement of Science

The selected publications each biography lists, which is a reading of that person rather than a reading of the year.

• 2009A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)

  Annals of Oncology

• 2009A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from color...

  Annals of Oncology

• 2009American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment

  Journal of Clinical Oncology

• 2009Aprepitant for the prevention of chemotherapy‐induced nausea and vomiting in adolescents

  Pediatric Blood & Cancer

• 2009CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

  Cell

• 2009Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection

  Pediatric Blood & Cancer

• 2009Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhi...

  Clin Cancer Res

• 2009Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

  Nature Medicine

• 2009Current evidence on the burden of head and neck cancers in Nigeria

  Head & Neck Oncology

• 2009Development of a second-generation antiandrogen for treatment of advanced prostate cancer

  Science

• 2009Distinctive chromatin in human sperm packages genes for embryo development

  Nature

• 2009Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data

  BMJ

• 2009Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year...

  Lancet Oncology

• 2009Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-co...

  Lancet Oncology

• 2009Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, ph...

  Lancet Oncology

• 2009Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

  Clinical Cancer Research

• 2009High incidence of hearing loss in long‐term survivors of multisystem Langerhans cell histiocytosis

  Pediatric Blood & Cancer

• 2009High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma (IELSG20)

  Lancet

• 2009Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support

  Virchows Archiv

• 2009HPV screening for cervical cancer in rural India

  New England Journal of Medicine

• 2009Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis

  Lancet

• 2009Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice

  PLoS Medicine

• 2009Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo

  Nature Immunology

• 2009Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept

  Physics in Medicine and Biology

• 2009Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer

  Journal of Clinical Oncology

• 2009Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children'...

  Journal of Clinical Oncology

• 2009Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt

  Nature Protocols

• 2009Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

  Radiotherapy and Oncology

• 2009Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

  Blood

• 2009Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)

  Radiotherapy and Oncology

• 2009One Step Forward Toward Identification of the Genetic Signature of Glioblastomas

  JAMA

• 2009Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis

  Proceedings of the National Academy of Sciences

• 2009Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

  Journal of Clinical Oncology

• 2009Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

  Blood

• 2009Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomise...

  Lancet

• 2009Rethinking screening for breast cancer and prostate cancer

  JAMA

• 2009Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multi...

  Cancer

• 2009Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor?

  Lung Cancer

• 2009Supervised risk predictor of breast cancer based on intrinsic subtypes (PAM50)

  JCO

• 2009Surgeon recommendations and receipt of mastectomy for treatment of breast cancer

  JAMA

• 2009The biology of chromatin remodeling complexes

  Annual Review of Biochemistry

• 2009The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung c...

  Journal of Thoracic Oncology

• 2009The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

  Journal of Clinical Oncology

• 2009The LKB1–AMPK pathway: metabolism and growth control in tumour suppression

  Nature Reviews Cancer

• 2009The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth

  Journal of Urology

• 2009Tratamiento combinado con antagonistas del calcio e inhibidores de la enzima de conversión de angiotensina (IECA) como terapia inicial preferible a diuréticos e...

  FMC - Formación Médica Continuada en Atención Primaria

• 2009Treating childhood acute lymphoblastic leukemia without cranial irradiation (Total Therapy XV)

  NEJM

• 2009Tumor Suppression by LKB1: SIK-ness Prevents Metastasis

  Science Signaling

• 2009Vasa Vasorum and Plaque Neovascularization on Contrast-Enhanced Carotid Ultrasound Imaging Correlates With Cardiovascular Disease and Past Cardiovascular Events

  Stroke